When MicroRNAs meet hypoxic pulmonary hypertension

Area of Science:

• Cardiovascular Research
• Pulmonary Medicine
• Molecular Biology

Background:

• Hypoxic pulmonary hypertension (HPH) is a severe cardiovascular condition linked to chronic hypoxia, causing pulmonary vascular remodeling and right heart failure.
• Current HPH treatments are limited due to poor understanding of disease mechanisms and lack of targeted therapies.
• MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and are implicated in HPH pathology.

Purpose of the Study:

• To review recent advances in understanding the role of miRNAs in HPH pathogenesis.
• To explore the clinical utility of miRNAs as biomarkers and therapeutic targets for HPH.
• To identify current challenges and future directions in HPH research.

Main Methods:

• Systematic review of current research on miRNAs in HPH.
• Focus on miRNA regulatory networks in pulmonary vasoconstriction, vascular remodeling, inflammation, and metabolic reprogramming.
• Analysis of clinical applications and translational prospects of miRNA-based strategies.

Main Results:

• miRNAs play central roles in HPH processes like vasoconstriction, smooth muscle cell proliferation/apoptosis, endothelial-Mesenchymal transition (EndMT), inflammation, and metabolic changes.
• miRNAs show potential as diagnostic and prognostic biomarkers for HPH.
• Targeting miRNAs presents a promising therapeutic avenue for HPH.

Conclusions:

• miRNAs are critical regulators in HPH development and progression.
• Further research into miRNA networks can lead to novel diagnostic tools and effective treatments for HPH.
• Translational studies are needed to fully realize the clinical potential of miRNAs in managing HPH.